Mean body mass index (BMI) was 25.01 kg/m2 in MetS and 24.165 in NMetS patients. The waist circumference mean was 92.7 �� 10.3 cm in MetS and 84.9 �� 8.25 cm in NMetS patients. However, triglycerides were 186.12 �� 76.5 mg/dl in MetS and 156.82 �� 75.43 mg/dl in NMets patients (P < 0.001). HDL levels were 23.77 �� 10.1 mg/dl in MetS, compared to 33.47 selleckbio �� 16 mg/dl in NMetS patients. The overall systolic blood pressure was 130 �� 13.7 mm Hg in MetS and 118.17 �� 7.95 mm Hg in NMetS, and diastolic blood pressure was 84.36 �� 7.65 mm Hg in MetS and 77.85 �� 5.53 in NMetS patients. Fasting blood glucose level was 116.12 �� 55.4 mg/dl in MetS and 111.58 �� 34.6 mm Hg in NMetS. Table 5 also depicts the prevalence of MetS and NMetS according to gender and age.
Men and women aged between 51 and 60 years suffered more frjom MetS, followed by those from 41 to 50 years of age. 26.66% of total diabetic patients were not suffering from MetS. 73.33% of total diabetic patients were suffering from MetS. Mean age was 52.8 years in MetS and 51.3 years in NMetS. Table 5 Mean �� SD of the components of the metabolic syndrome versus non-metabolic syndrome according to gender Table 6 presents the top 12 drugs utilized concomitantly in MetS patients with type 2 diabetes; anti-diabetics were found to be highly used (33.2%), followed by vitamins (20.7%), anti-ulcer drugs (17.84%), antihypertensives (11.61%), analgesics and antipyretics (4.9%), anti-inflammatory drugs (4.14%), antibiotics (2.5%), anti-allergic drugs (1.7%), hyperlipidemic drugs (1.7%), anti-angina drugs (0.8%), anti-diarrheal (0.
4%), and anti-platelet drugs (0.4%). Table 6 Top 12 drugs utilized concomitantly with metabolic syndrome in diabetes mellitus Table 7 shows the Indian Diabetes Risk Score (IDRS) which was developed based on multiple logistic regression analysis. In 2007, Mohan et al. reported that IDRS was calculated using four simple variables, namely age, family history, regular exercise, and waist circumference. The individuals were classified as being at high risk (score > 60), moderate risk (score 30�C50), and low risk (score < 30) out of total score. 55% of MetS patients had high score, followed by 43.63% of patients with moderate score and 1.8% with low score. High score leads to the development of cardiovascular disease. Score was calculated on the basis of Figure 1.
Even patients with NMetS had a high score (45%), followed by moderate 35% and low (20%) scores. Table 7 Indian diabetes risk score (IDRS) developed based on multiple logistic regression analysis Figure 1 Indian diabetes risk score (IDRS) DISCUSSION This study analyzed the incidence of the Dacomitinib MetS and NMetS among type 2 diabetic patients attending diabetic outpatient clinic at a tertiary care hospital, using the recently introduced definition of the MetS by the NCEP-ATP III guidelines.